The Hidden Environmental Toll: New Links Between Industrial Pollution and Progressive Supranuclear Palsy on October 28, 2026October 29, 2026 Posted by Nila Kartika Wati
The Hidden Heart Risk: How Nighttime Light Pollution Is Quietly Remodeling Our Cardiovascular Health on October 28, 2026 Posted by
The AI Revolution: Navigating Your Career in the Age of Intelligent Automation on October 28, 2026 Posted by
The Metabolic Paradox: Turning a Cancer’s Ally into an Immune System Weapon on October 28, 2026 Posted by
Pioneering Wellness: Dr. Angela Neal-Barnett’s Decades-Long Fight Against Anxiety in the Black Community on October 28, 2026 Posted by
Beyond the Label: New Research Reveals How Sweeteners and Medications Reshape the Gut Microbiome on October 28, 2026 Posted by
The Hidden Environmental Toll: New Links Between Industrial Pollution and Progressive Supranuclear Palsy on October 28, 2026October 29, 2026 Posted by Nila Kartika Wati
The Hidden Heart Risk: How Nighttime Light Pollution Is Quietly Remodeling Our Cardiovascular Health on October 28, 2026 Posted by
The AI Revolution: Navigating Your Career in the Age of Intelligent Automation on October 28, 2026 Posted by
Posted in Medical Innovations Novartis Bets Big on Brain-Delivery Tech in $125M Sironax Acquisition on September 16, 2026
Posted in Digital Health Tools Novartis Bets $125M on Sironax Brain-Delivery Tech Amid Neuroscience Pipeline Turbulence on September 16, 2026
Posted in Digital Health Tools Pharma Market Volatility: Novartis Faces Investor Skepticism as Biosimilar Pipeline Stalls on September 11, 2026
Posted in Digital Health Tools Pharma Industry Turbulence: Novartis Under Fire and the Evolution of U.S. Drug Pricing on September 11, 2026
Posted in Medical Innovations A Difficult Week for Big Pharma: Novartis and Novo Nordisk Face High-Stakes R&D Setbacks on September 9, 2026
Posted in Medical Innovations Novartis Faces Investor Backlash After $12B Bet on Del-Desiran Hits Clinical Wall on September 8, 2026
Posted in Medical Innovations A Major Setback in Cardiology: Novartis’ Pelacarsen Fails Pivotal Phase 3 Trial on September 4, 2026
Posted in Medical Innovations Novartis’ Remibrutinib: A Potential Paradigm Shift in the High-Stakes Race for BTK Inhibition on September 1, 2026
Posted in Medical Innovations Setback in the "Immune Reset" Frontier: Novartis and Bristol Myers Pause CAR-T Autoimmune Trials on August 31, 2026
Posted in Medical Innovations Novartis’ Pacibekitug Shows Promise in Midstage Cardiovascular Trial: A New Frontier in Inflammation Management on August 29, 2026
